In an interview to CNBC-TV18, S Ramesh of Lupin said the National Pharmaceutical Pricing Authority, or NPPA, adding more drugs to price control is a retrograde step. He further added that it'll be negative for the company, but couldn't quantify the financial impact.
In an interview to CNBC-TV18, S Ramesh of Lupin said the National Pharmaceutical Pricing Authority, or NPPA, adding more drugs to price control is a retrograde step. He further added that it'll be negative for the company, but couldn't quantify the financial impact.
Lupin stock price
On July 14, 2014, at 09:20 hrs Lupin was quoting at Rs 1051.15, down Rs 2.3, or 0.22 percent. The 52-week high of the share was Rs 1102.45 and the 52-week low was Rs 742.30.
The company's trailing 12-month (TTM) EPS was at Rs 51.82 per share as per the quarter ended March 2014. The stock's price-to-earnings (P/E) ratio was 20.28. The latest book value of the company is Rs 155.60 per share. At current value, the price-to-book value of the company is 6.76.
Anda sedang membaca artikel tentang
NPPA adding more drugs a retrograde step: Lupin
Dengan url
http://sehatkafein.blogspot.com/2014/07/nppa-adding-more-drugs-retrograde-step.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
NPPA adding more drugs a retrograde step: Lupin
namun jangan lupa untuk meletakkan link
NPPA adding more drugs a retrograde step: Lupin
sebagai sumbernya
0 komentar:
Posting Komentar